Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B7-H3/CD276 is a multifunctional immune checkpoint molecule with complex roles spanning immunoregulation and direct promotion of malignancy. Its restricted expression pattern makes it an attractive target for next-generation cancer immunotherapies currently under clinical investigation. However, further research into its ligands/receptors and signaling pathways remains necessary for fully realizing its therapeutic potential.
Monoclonal antibody, Antibody-drug conjugate, CAR-T cell therapy, Nanobody-based approach
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B7-H3 Protein (CD276).